In vitro mycobacterial growth inhibition assays: A tool for the assessment of protective immunity and evaluation of tuberculosis vaccine efficacy
Tuberculosis (TB) continues to pose a serious global health threat, and the current vaccine, BCG, has variable efficacy. However, the development of a more effective vaccine is severely hampered by the lack of an immune correlate of protection. Candidate vaccines are currently evaluated using precli...
Main Authors: | Mcshane, H, Tanner, R, O'Shea, M, Fletcher, H |
---|---|
Format: | Journal article |
Published: |
Elsevier
2017
|
Similar Items
-
Tools for assessing the protective efficacy of TB vaccines in humans: in vitro mycobacterial growth inhibition predicts outcome of in vivo mycobacterial infection
by: Tanner, R, et al.
Published: (2020) -
The influence of haemoglobin and iron on in vitro mycobacterial growth inhibition assays
by: Tanner, R, et al.
Published: (2017) -
The in vitro direct mycobacterial growth inhibition assay (MGIA) for the early evaluation of TB vaccine candidates and assessment of protective immunity: a protocol for non-human primate cells
by: Tanner, R, et al.
Published: (2021) -
A new tool for tuberculosis vaccine screening: Ex vivo Mycobacterial Growth Inhibition Assay indicates BCG mediated protection in a murine model of tuberculosis
by: McShane, H, et al.
Published: (2016) -
A mycobacterial growth inhibition assay (MGIA) for bovine TB vaccine development
by: Pepponi, I, et al.
Published: (2017)